Akums brings a patient-friendly twist to migraine care with Lasmiditan dispersible tablets 

Key Highlights: 

• Akums has introduced the world’s first Lasmiditan dispersible tablets, approved by the Drugs Controller General of India, offering a more convenient way to manage acute migraine attacks. 

• What makes this interesting is the dispersible format, instead of swallowing a pill during a migraine (often difficult due to nausea or vomiting), patients can mix it in water. Plus, its dual disintegration mechanism helps the drug act faster when relief is needed most. 

• As a selective 5-HT1F agonist, Lasmiditan works directly on migraine pathways, and with added taste-masking and easier intake, this version makes treatment not just effective but far more practical during real migraine episodes. 

Implications: 

The dispersible format gives Akums a clear differentiation edge in the acute migraine space, directly addressing nausea and swallowing difficulties that often limit real-world use of standard tablets. 
By pairing a next‑gen, neurally targeted mechanism (5‑HT1F agonism) with a more practical, patient‑centric dosage form, Akums strengthens its positioning as an innovation-led CDMO partner for CNS and specialty brands in India and export markets. 

Source: Express Pharma | Image: Akums